To the Editor: Chen et al. report that SJS-TEN did not develop in subjects testing negative for HLA-B*1502 who received carbamazepine. After genotyping HLA-B in 11 patients who had carbamazepine-induced SJS-TEN and who were of southern Han Chinese origin, we observed that 3 of these patients were negative for HLA-B*1502. Rather, they carried HLA-B*1511/1511, 5401/5401, and 4001/4601. Some early studies 1 suggested that Han Chinese persons with carbamazepineinduced SJS-TEN who lived in Taiwan, Hong Kong, or some Southeast Asian countries were almost all HLA-B*1502 carriers. More recent studies have reported more instances of SJS-TEN among persons who were negative for HLA-B*1502. 2 Since it has been reported that European and Japanese patients with carbamazepine-induced SJS-TEN were negative for HLA-B*1502, 3 we suggest that the risk of this disorder is not nil in such patients and that physicians should be vigilant about the possibility of this disorder in patients receiving carbamazepine, regardless of their HLA-B genotype.
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